Reexamining the optimal nuchal translucency cutoff for diagnostic testing in the cell-free DNA and microarray era: results from the Victorian Perinatal Record Linkage study-Reference-Cited by-同舟云学术

Reexamining the optimal nuchal translucency cutoff for diagnostic testing in the cell-free DNA and microarray era: results from the Victorian Perinatal Record Linkage study

Published:2021-11 Issue:5 Volume:225 Page:527.e1-527.e12
ISSN:0002-9378
Container-title:American Journal of Obstetrics and Gynecology
language:en
Short-container-title:American Journal of Obstetrics and Gynecology

Author:

Hui Lisa^ORCID,Pynaker Cecilia,Bonacquisto Leonard,Lindquist Anthea,Poulton Alice,Kluckow Eliza,Hutchinson Briohny,Norris Fiona,Pertile Mark D.,Gugasyan Lucy,Kulkarni Abhijit,Harraway James,Howden Amanda,McCoy Richard,da Silva Costa Fabricio,Menezes Melody,Palma-Dias Ricardo,Nisbet Debbie,Martin Nicole,Bethune Michael,Poulakis Zeffie,Halliday Jane

Funder

National Health and Medical Research Council

University of Melbourne

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology

Reference21 articles.

1. Current use of noninvasive prenatal testing in Europe, Australia and the USA: a graphical presentation;Gadsbøll;Acta Obstet Gynecol Scand,2020

2. State-wide utilization and performance of traditional and cell-free DNA-based prenatal testing pathways: the Victorian Perinatal Record Linkage (PeRL) study;Lindquist;Ultrasound Obstet Gynecol,2020

3. ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practice;Salomon;Ultrasound Obstet Gynecol,2017

4. Genomic microarray in fetuses with increased nuchal translucency and normal karyotype: a systematic review and meta-analysis;Grande;Ultrasound Obstet Gynecol,2015

5. Cut-off value of nuchal translucency as indication for chromosomal microarray analysis;Maya;Ultrasound Obstet Gynecol,2017

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing fetal diagnosis and prognostication using comprehensive prenatal phenotyping and genetic testing;Pediatric Research;2024-06-27

2. Associations between genomic aberrations, increased nuchal translucency, and pregnancy outcomes: a comprehensive analysis of 2,272 singleton pregnancies in women under 35;Frontiers in Medicine;2024-04-03

3. Is Nuchal Translucency of 3.0–3.4 mm an Indication for cfDNA Testing or Microarray? – A Multicenter Retrospective Clinical Cohort Study;Fetal Diagnosis and Therapy;2024

4. Ersttrimester-Klinik zum Zeitpunkt 11–13+6 Schwangerschaftswochen: Screening, Risikoberechnung und Management;Springer Reference Medizin;2024

5. Ersttrimester-Klinik zum Zeitpunkt 11–13+6 Schwangerschaftswochen: Screening, Risikoberechnung und Management;Springer Reference Medizin;2024